Search results

This joint initiative at ANSTO has developed a new capability: solid surface radiolabelling to evaluate Auger emitting sources for next-generation targeted therapy.

Accelerator Mass Spectrometry (AMS) is an ultra-sensitive analytical technique based on the use of an ion accelerator as a powerful mass spectrometer.

Outstanding individuals and teams have been recognised for their outstanding work, innovation, excellence in the 2025 ANSTO Awards. 

Excellent radiolabelling facilities and the operation of OPAL, a world-class multi-purpose nuclear reactor, enable ANSTO to produce a large range of radioisotopes for Australian researchers in both radiopharmaceutical and environmental areas.

Three ANSTO staff members were involved in a chemical spill this morning when approx 250mL of sodium hydroxide was released from a pipe.

A large international team has provided an understanding of how nanoscale interactions affect the thermal stability of a type of next generation organic solar cells.

ANSTO sets out the following terms and conditions relating to users who access our facilities for the purpose of research.

ANSTO has secured a $1.62 million Medical Research Future Fund (MRFF) grant under the Australian Brain Cancer Mission’s 2024 Brain Cancer Discovery and Translation program, administered by the Department of Health and Aged Care.  

An international team led by ANSTO has been awarded a prestigious program grant from the Foundation for Australia-Japan Studies.

Researchers use Kitaev theoretical model to explain unusual phenomenon in two-dimensional material.

Four international authorities will deliver plenary addresses virtually at the 15th International Conference on Accelerator Mass Spectrometry (AMS15) , which will be held online from 15-19 November.

ANSTO’s Innovation Precinct has been highlighted in the Greater Sydney Commission’s South District Plan.

The complex engineering of scientific instruments is explored in this 'behind the scenes' look at the installation of frontends for two new beamlines at the Australian Synchrotron.

Australian clean energy technology company, entX Limited is taking advantage of ANSTO’s unique capacity to generate tailored radioisotope products in the OPAL multi-purpose nuclear reactor to advance a series of innovative projects.